

One in four people in Canadian federal prisons have been previously exposed to hepatitis C. Hepatitis C can…

While pursuing my PhD in medical anthropology at Simon Fraser University, I spent two years in Ghana critically…

Somewhere between 1 in every 200 to 800 babies are born infected with cytomegalovirus (CMV). If undiagnosed, it…
Randomized Trial to Prevent Vascular Events in HIV REPRIEVE is the first large-scale randomized clinical research trial to test a strategy for heart disease prevention among people living with HIV. Specifically, REPRIEVE will test whether a daily dose of a statin (pitavastatin) reduces the risk of heart disease among people living with HIV.
CTN+ Researchers are the backbone of the Network through generating ideas, collaborating on new initiatives, conducting research, and sharing their knowledge.
Explore Our NetworkInterested in joining the CTN+? We’re always on the lookout for new members to answer the most pressing research questions of today, while anticipating the questions of tomorrow.
Learn More